Author: Purple Foxy

The funding, led by existing investors BioAdvance and Wellness Coaches, follows additional 3rd party studies by University College London and LateralDx, confirming that Senzo’s Amplified Lateral Flow (ALF) platform returned greater than 98% accuracy against PCR, including in low viral-load samples

A person holding a Senzo Amplified Lateral Flow test.

PHILADELPHIA – December 12, 2022 – (Newswire.com)

Senzo, a life sciences company developing high accuracy, low-cost point-of-care diagnostic technologies, today announced a $1.9 million investment led by existing investors BioAdvance and Wellness Coaches.

The funding follows recent blinded studies by UCL and LateralDx, confirming that the Senzo Amplified Lateral Flow test had 98% accuracy in comparison to PCR in correctly identifying COVID-19 virus in samples, even at very low viral loads above 30 Ct. These studies, combined with an earlier study by Sheffield University, demonstrate the high performance of the Senzo Amplified Lateral Flow (ALF) platform. ALF is the only platform that combines the speed and low cost of lateral flow tests with the accuracy of PCR tests.

The investment will be used to complete validation, execute clinical trials, secure FDA EUA authorization, and scale manufacturing for the ALF COVID-19 test, as well as to advance R&D for new Flu A/B, RSV, Tuberculosis, HIV, Hepatitis-C, and Strep tests.

“This funding further indicates the interest and excitement investors have in the ALF platform, and is another important step in bringing our technology to market. Whether for COVID-19, TB, Flu, or a range of other diseases, there are patients in desperate need of better at-home, rapid-test diagnostics, and a huge market needing our tests. This investment will help us bring this innovative technology to market even faster,” said Jeremy Stackawitz, CEO of Senzo Health.

Senzo plans to complete ALF COVID-19 clinical trials and secure FDA EUA regulatory approval in 1H 2023, with tests commercially available in the 2H 2023.

About Senzo:

Senzo is an in vitro diagnostics company developing innovative, accurate, and accessible testing products. Senzo was founded with the vision of utilizing novel technologies, with a focus on enhanced sensitivity, to create mobile, point-of-care and self-testing products and devices with the ability to accurately, quickly, and cost-effectively conduct testing where healthcare professionals and patients need it most. Senzo is creating game-changing products and systems which bring testing to the patient, eliminating the need for the current slow, expensive central-lab testing paradigms.

About BioAdvance:

BioAdvance is an early-stage life sciences fund with a focus in the mid-Atlantic region, investing up to $1.5 million initially and up to $5 million over the lifetime of companies with the potential to significantly improve human health. www.bioadvance.com.

About Wellness Coaches:

Wellness Coaches is one of the largest and most-experienced tech-enabled wellness, nutrition, clinical, and injury prevention service providers, utilizing both onsite and virtual expertise to help communities and organizations increase engagement, improve population health, mitigate safety risks, and reduce healthcare and workers’ compensation costs. www.wcusa.com. 

For more information, visit https://www.senzo.com.

Press Contact:
Alex Mohacs
alex@senzo.com

Contact Information:

Alex Mohacs

Sales & Marketing

alex@senzo.com

Press Release Service
by
Newswire.com

Original Source:

Senzo Secures Additional $1.9MM Equity Funding for Its PCR-Accurate Lateral Flow Test

As mental health disorders increasingly impact global populations, Gb Sciences is developing psychotropic but non-psychedelic treatments for anxiety and depression that compete with the emerging billion-dollar psychede…

LEONA VALLEY, Calif. – December 9, 2022 – (Newswire.com)

Leona Val…

After a month dedicated to Cyber Security in October, the situation is now high-risk for many organizations. Cyber attacks are increasing, and the healthcare Industry is often specifically targeted. Whether the breach is due to ransomware attacks or poorly secured Remote Desktop connections, TSplus offers a solution for the Healthcare system.

TSplus Has a Solution for Healthcare Cybersecurity
TSplus offers secure remote desktop solutions ideal for the Healthcare Industry’s needs in Cybersecurity

IRVINE, Calif. – December 9, 2022 – (Newswire.com)

Hospitals and health facilities have become easy targets for malicious actors as these have been under immense strain due to the pandemic.  

Nearly 1.9 million cyberattacks against the healthcare industry in India were recorded from January to November this year, according to research led by local cybersecurity think-tank CyberPeace Foundation. More recently, The Keralty multinational healthcare organization, the leading healthcare system in Colombia, suffered a ransomware attack disrupting the websites and operations of the company and its subsidiaries. 

Because of the general use of remote access to centralize medical records, booking systems and invoices, which presents security risks, most of the attacks target internet-facing systems with open RDP ports. Those where server message block and database services are enabled, and those that run old Windows server platforms. Trojan viruses and Brute force attacks are also used to gain network access and steal patient data. All of this stolen data is sold on the dark web. This month, stolen data on African, Middle East and Turkish firms were on sale for $2,100, according to a report by Kaspersky.

TSplus offers a solution that combines smart remote access technologies and advanced protection for the safe use of Remote Desktop in the Healthcare system.

A Solution for Secure Remote Desktop and Server Protection 

TSplus provides secure remote desktop solutions to hundreds of medical organizations in the World, allowing thousands of hospitals and clinics to run full speed and save on IT costs. Furthermore, TSplus has developed a unique cybersecurity program for Remote Desktop to ensure that remote connections and data exchanged on hospital networks stay safe: Advanced Security. 

In a few clicks, TSplus Advanced Security blocks attacks on Remote Desktop and Application Servers with powerful security features all combined in a unique tool. Among included features are Geo-restriction, brute-force attack defender, ransomware protection, and even a global hacker IP protection which, in one go, blocks over 600 million known hacker IP addresses from day 1 of use. It is the most comprehensive and cost-attractive cybersecurity toolbox on the market.  

A smart solution for the healthcare industry at a time of deep need.

The TSplus suite of software can be tested and purchased directly from www.tsplus.net.

Contact Information:

Floriane Mer

Marketing Manager

floriane.mer@tsplus.net

Press Release Service
by
Newswire.com

Original Source:

TSplus Has a Secure Remote Desktop Solution for HealthCare Industry

BIRMINGHAM, Ala. – December 8, 2022 – (Newswire.com)

BioGX, a global provider of easy molecular diagnostic solutions since 2007, announced the Ex-US commercial release of its portable pixl™ qPCR real-time PCR platform for use with BioGX CE-IVD marked assays, enabling global access and complementing the recent US FDA EUA expanded use of Xfree™ COVID-19 Direct RT-PCR on the pixl.

The pixl instrument is a benchtop 4-channel, 16-well, RT-PCR instrument that supports rapid turnaround times for batches of up to 16 samples, with integrated results interpretation on a device with the compact footprint of a touchpad.

“pixl, combined with our unique Xfree chemistry, offers a low-cost direct-sample-to-answer PCR solution on a portable, compact device. pixl will provide broader access to clinical laboratories for decentralized PCR testing, enabling faster, better, low-cost near-patient molecular diagnostics,” said Shazi Iqbal, Ph.D., CEO of BioGX.

This platform was previously CE-IVD marked and can be used with the following BioGX CE-IVD marked assays:

• Xfree COVID-19 (N1-gene) Direct RT-PCR
• Xfree COVID-19 (N1/RdRp), Flu A, Flu B
• Xfree Group A Streptococcus

Starting January 2023, BioGX will make additional syndromic tests available on the pixl platform from its large menu of lyophilized multiplex assays, including the Research Use Only (RUO) Direct-Sample assays: Xfree Human Monkeypox (hMPXV), Xfree HSV1/HSV2/VZV and Xfree Treponema pallidum (Syphilis). The Xfree assay format is compatible with most commonly used transport/collection media types and can be validated with a wide variety of patient sample collections. 

Additional information can be requested by contacting BioGX at Ph: +1.205.250.8055 or info@biogx.com. 

About BioGX

BioGX is a leading global provider of lyophilized real-time PCR reagents for molecular diagnostics. BioGX, Inc., headquartered in Birmingham, Alabama, and Dallas, TX, and its wholly owned subsidiary BioGX B.V., based in Amsterdam, The Netherlands, (collectively “BioGX”), operates in a cGMP compliant environment certified to ISO 13485 medical device development and manufacturing standards. The proprietary Sample-Ready^™ technology is at the core of all product offerings for Clinical, Food Safety, Pharma QC and Water Quality molecular testing. BioGX’s 60+ multiplex real-time PCR products are marketed and sold in several countries through its Global Distribution Network. 

For more information on BioGX, please visit BioGX.com.

Sample-Ready, Just Add Water, Xfree and pixl are trademarks of BioGX, Inc.

Contact Information:

Mohammed Merchant

Sr. Director, Marketing

marketing@biogx.com

(205) 250-8055

Press Release Service
by
Newswire.com

Original Source:

BioGX Launches ‘pixl™’ Portable qPCR Platform Ex-US With Expanded Test Menu for Infectious Diseases

Michael Holland as Chief Development Officer, Sampath Narayanan as Chief Information Officer, and Kimberly Shreve as Chief Compliance and Privacy Officer

…

With growing membership numbers, the health insurance alternative boasts medical bill crowdfunding, Care Advocates, and an option to invest in Bitcoin.

…

Aronora co-founder and CEO Dr. Erik Tucker has been elected as Fellow of the National Academy of Inventors (NAI)

Dr. Erik Tucker, CEO of Aronora …

Gymera, one of the fastest-growing high-tech companies, has officially unveiled its latest intelligent fitness system. This revolutionary device can help work out full body in the most efficient and interactive way.
…

Harm Reduction Box This is a real Narcan Distribution box in Michigan.
YOAKUM, Texas – December 8, 2022 – (Newswir…